Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
RATIONALE: Premature discontinuation of antidepressant drugs is a frequent clinical problem. Adverse effects are common, occur early on in treatment and are reported to be one of the main reasons for discontinuation of antidepressant treatment. OBJECTIVES: To investigate the association between adverse effects occurring in the first 2 weeks of antidepressant treatment and discontinuation by 6 weeks as the outcome. To investigate the time profile of adverse effects induced by the selective serotonin reuptake inhibitor citalopram and the noradrenaline reuptake inhibitor reboxetine over 12 weeks of treatment. METHODS: Six hundred and one depressed individuals were randomly allocated to either citalopram (20 mg daily) or reboxetine (4 mg twice daily). A modified version of the Toronto Side Effects Scale was used to measure 14 physical symptoms at baseline (medication free) and at 2, 6 and 12 weeks after randomisation. RESULTS: Individuals randomised to reboxetine reported a greater number of adverse effects and were more likely to stop treatment than individuals receiving citalopram. Dizziness (OR 1.83; 95% CI 1.09, 3.09; p = 0.02) and the total number of adverse effects (OR 1.12; 95% CI 1.00, 1.25; p = 0.06) reported at 2 weeks were associated with discontinuation from overall antidepressant treatment by 6 weeks. Reports of adverse effects tended to reduce throughout the 12 weeks for both antidepressants. CONCLUSIONS: The majority of adverse effects were not individually associated with discontinuation from antidepressant treatment. Reports of physical symptoms tended to reduce over time. The physical symptoms that did not reduce over time may represent symptoms of depression rather than antidepressant-induced adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“Depression is a chronic disorder affecting a relatively high proportion of individuals each year (Wittchen et al. 2011).”
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Lewis, G., Pelosi, A. J., Araya, R., & Dunn, G. (1992) · Psychological Medicine · doi:10.1017/s0033291700030415 · Cited by 1,487 · cited 5×
“…that fulfilled the ICD-10 criteria for depression (category F32), assessed using computerised Clinical Interview Schedule— revised version (CIS-R) (Lewis et al. 1992; WHO 1992; Lewis 1994), and a Beck Depression Inventory (BDI) (Beck et al. 1961) score above 14, were eligible to participate in…”
InfluentialSelf-citationAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“TCAs are less well tolerated than either SSRIs or selective noradrenaline reuptake inhibitors (NARIs) potentially due to their broader pharmacologic mechanism of action (Anderson 2000).”
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 10×
“The GENPOD study has allowed a detailed comparison between two pharmacologically different antidepressants, citalopram and reboxetine.”
InfluentialKessler, D., Lewis, G., Kaur, S., Wiles, N., King, M., Weich, S., Sharp, D. J., Araya, R., Hollinghurst, S., & Peters, T. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61257-5 · Cited by 387 · cited 2×
“…the similar scores on depressive scales and similar response rates to antidepressant treatment seen in other UK depression trials (Ward et al. 2000; Kessler et al. 2009) and the US STAR*D study (Trivedi et al. 2006), the GENPOD sample is a representative of a typical sample of primary care…”
Self-citationHu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235
Goldstein, B. J., & Goodnick, P. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003041 · Cited by 171 · cited 1×
“Despite their superior adverse effect profile compared with the older generation of tricyclic antidepressants (TCAs), SSRIs frequently cause gastrointestinal adverse effects, insomnia, headache, anxiety and sexual dysfunction (Goldstein and Goodnick 1998; Ferguson 2001a).”
EVANS, M., KESSLER, D., LEWIS, G., PETERS, T. J., & SHARP, D. (2004) · Psychological Medicine · doi:10.1017/s0033291703008055 · Cited by 80
Self-citation
Research works printed but not linked: 40
- Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, Tylee A, P. British Assoc (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343–396 · DOI · Paper page
- Andersson KE (2011) Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 63:811–859 · DOI · Paper page
- Bailey JE, Potokar J, Coupland N, Nutt DJ (1995) The 5-HT3 antagonist ondansetron reduces gastrointestinal side-effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9:137–141 · DOI · Paper page
- Beck AT, Erbaugh J, Ward CH, Mock J, Mendelsohn M (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571 · DOI · Paper page
- Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW (2002) Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36:578–584 · doi:10.1345/aph.1a254 · Paper page
- Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE (2003) Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18:151–156
- Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201 · DOI · Paper page
- Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001) Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62:30–33 · DOI · Paper page
- Donoghue J, Tylee A, Wildgust H (1996) Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–5. Br Med J 313:861–862 · DOI · Paper page
- Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR (1999) Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 13:136–143 · DOI · Paper page
- Eyding D, Lelgemann M, Grouven U, Haerter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737 · DOI · Paper page
- Ferguson JM (2001b) The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62:22–34 · DOI · Paper page
- Frank E, Judge R (2001) Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. J Clin Psychiatry 62:10–15 · DOI
- Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J (2004) Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 26:1446–1455 · DOI
- Gruenberg AM (2009) Stahl's essential psychopharmacology: neuroscientific basis and practical applications, third edition. Psychol Med 39:520–521 · doi:10.1017/s0033291708005060
- Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EHF (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23–44 · DOI · Paper page
- Haug TT, Mykletun A, Dahl AA (2004) The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. Psychosom Med 66:845–851 · DOI · Paper page
- Krska J, Morecroft CW (2013) Patients' use of information about medicine side effects in relation to experiences of suspected adverse drug reactions: a cross-sectional survey in medical in-patients. Drug Saf 36:673–680 · doi:10.1007/s40264-013-0065-3
- Lamb GC, Green SS, Heron J (1994) Can physicians warn patients of potential side-effects without fear of causing those side effects. Arch Intern Med 154:2753–2756 · DOI
- Langworth S, Bodlund O, Agren H (2006) Efficacy and tolerability of reboxetine compared with citalopram—a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 26:121–127 · DOI · Paper page
- Lewis G (1994) Assessing psychiatric-disorder with a human interviewer or a computer. J Epidemiol Community Health 48:207–210 · DOI · Paper page
- Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D (2011) Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry 198:464 · DOI · Paper page
- Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105:164–172 · DOI · Paper page
- Masand PS (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:2289–2304 · DOI · Paper page
- Middleton HC, Nutt DJ, Anastassiades P (1988) Evidence that imipramine-induced postural hypotension may be centrally mediated. Hum Psychopharmacol Clin Exp 3:181–190 · doi:10.1002/hup.470030305
- Moeller HJ (2001) Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 251:13–20 · DOI
- Montgomery SA, Bebbington P, Cowen P, Deakin W, Freeling P, Hallstrom C, Katona C, King D, Leonard B (1993) Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 7:19–23 · DOI
- Morehouse R, MacQueen G, Kennedy SH (2011) Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 132:S14–S20 · DOI
- NHS (2011) Prescription Cost Analysis England 2010. P. U. NHS Information Centre for Health and Social Care, London
- Nutt DJ, Glue P (1991) Imipramine in panic disorder. 2. Effects on alpha2-adrenoceptor function. Journal of psychopharmacol (Oxford, England) 5:135–141 · DOI
- Schweitzer I, Maguire K, Ng C (2009) Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 43:795–808 · DOI · Paper page
- StataCorp (2011) Stata statistical software. College station. StataCorp LP, TX
- Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, Nutt D, O'Donovan M, Sharp D, Peters T, Lewis G (2008) GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 9:29 · DOI
- Thompson AJ (2013) Recent developments in 5-HT3 receptor pharmacology. Trends Pharmacol Sci 34:100–109 · DOI
- Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ (2009a) Adverse reactions to antidepressants. Br J Psychiatry 195:202–210 · DOI · Paper page
- Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P (2009b) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194:252–259 · DOI · Paper page
- Vanderkooy J, Kennedy SH, Bagby RM (2002) Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 47:174–180 · DOI · Paper page
- Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, Gabbay M, Tarrier N, Addington-Hall J (2000) Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. Br Med J 321:1383–1388 · DOI · Paper page
- Warden D, Trivedi MH, Wisniewski SR, Kurian B, Zisook S, Kornstein SG, Friedman ES, Miyahara S, Leuchter AF, Fava M, Rush AJ (2010) Early adverse events and attrition in selective serotonin reuptake inhibitor treatment a suicide assessment methodology study report. J Clin Psychopharmacol 30:259–266 · DOI
- Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G (2012) Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry 200:130–136 · DOI
Cited by
A review of depression and suicide risk assessment using speech analysis
Cummins, N., Scherer, S., Krajewski, J., Schnieder, S., Epps, J., & Quatieri, T. F. (2015) · Speech Communication · doi:10.1016/j.specom.2015.03.004 · Cited by 1,003
Automated assessment of psychiatric disorders using speech: A systematic review
Low, D. M., Bentley, K. H., & Ghosh, S. S. (2020) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.354 · Cited by 509
Maintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192
Self-citationLewis, G., Duffy, L., Ades, A., Amos, R., Araya, R., Brabyn, S., Button, K. S., Churchill, R., Derrick, C., Dowrick, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30366-9 · Cited by 120
Self-citationDuffy, L., Bacon, F., Clarke, C. S., Donkor, Y., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., King, M., et al. (2019) · Trials · doi:10.1186/s13063-019-3390-8 · Cited by 22
Self-citation
Metadata
- Authors
- Crawford, A. A., Lewis, S., Nutt, D., Peters, T. J., Cowen, P., O’Donovan, M. C., Wiles, N., & Lewis, G.
- Venue
- Psychopharmacology
- Published
- 2014-02-13
- Volume
- 231
- Issue
- 15
- Pages
- 2921-2931
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1968895338
- Cited by
- 69
- References
- 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. https://app.cochat.ai/papers/10.1007/s00213-014-3467-8
- The paper
- Crawford, A. A., Lewis, S., Nutt, D., Peters, T. J., Cowen, P., O’Donovan, M. C., Wiles, N., & Lewis, G. (2014). Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology. https://doi.org/10.1007/s00213-014-3467-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.